Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00CVJ
|
||||
| Former ID |
DNCL003143
|
||||
| Drug Name |
Neu-P11
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Insomnia [ICD9: 307.41, 307.42, 327.0, 780.51, 780.52; ICD10:F51.0, G47.0] | Phase 2 | [1] | ||
| Company |
Neurim Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C17H16N2O4
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 1A receptor | Target Info | Agonist | [2] | |
| 5-hydroxytryptamine 1D receptor | Target Info | Agonist | [2] | ||
| Melatonin receptor | Target Info | Agonist | [3] | ||
| KEGG Pathway | cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Serotonergic synapsehsa04024:cAMP signaling pathway | |||||
| Serotonergic synapsehsa04080:Neuroactive ligand-receptor interaction | |||||
| Circadian entrainment | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| 5HT1 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| 5HT1 type receptor mediated signaling pathway | |||||
| Reactome | Serotonin receptors | ||||
| G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors | |||||
| G alpha (i) signalling eventsR-HSA-373076:Class A/1 (Rhodopsin-like receptors) | |||||
| G alpha (i) signalling events | |||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | ||||
| SIDS Susceptibility Pathways | |||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP722:Serotonin HTR1 Group and FOS Pathway | |||||
| GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like | |||||
| Small Ligand GPCRs | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01489969) Sleep Laboratory Study to Investigate the Safety and Efficacy of Neu-P11 in Primary Insomnia Patients. U.S. National Institutes of Health. | ||||
| REF 2 | Clinical pipeline report, company report or official report of Neurim Pharmaceuticals. | ||||
| REF 3 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 288). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.